Form D · Pharmaceuticals
Esanik Therapeutics, Inc.
Northville, MI · CIK 0002044524
Offering snapshot reported Apr 30, 2026 · SEC filing
- Reported sold
- $200K Offering amount: $375K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 6, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 30, 2026 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Nov 14, 2024 | Initial | $3,278,915 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-582376
Source: Form D, filed Apr 30, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Mel Sorensen | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
120 West Main Street
Northville, MI, 48167
Northville, MI, 48167